Nature's Sunshine(US:NATR)2025-11-06 22:11Sales Performance - Consolidated net sales for the three months ended September 30, 2025, were $128.3 million, representing a 12.0% increase compared to $114.6 million in the same period of 2024[106] - For the nine months ended September 30, 2025, consolidated net sales were $356.3 million, an increase of 6.0% from $336.2 million in 2024[106] - Net sales in Asia for the three months ended September 30, 2025, were $64.7 million, a 17.1% increase from $55.3 million in 2024[107] - In Europe, net sales for the three months ended September 30, 2025, were $22.1 million, up 12.7% from $19.6 million in 2024[112] - North America net sales for the three months ended September 30, 2025, were $36.2 million, reflecting a 7.7% increase from $33.6 million in 2024[113] - Latin America and Other markets saw net sales decrease to $5.3 million for the three months ended September 30, 2025, down 13.1% from $6.1 million in 2024[115] Cost and Expenses - Cost of sales as a percentage of net sales decreased to 26.7% for the three months ended September 30, 2025, compared to 28.7% in 2024[117] - Volume incentives as a percentage of net sales were 30.7% for the three months ended September 30, 2025, down from 31.0% in 2024[118] - Selling, general and administrative expenses increased to $45.7 million for the three months ended September 30, 2025, compared to $40.9 million in 2024[120] Income and Taxes - Other income, net for the three and nine months ended September 30, 2025, was $0.7 million and $4.9 million, respectively, compared to $2.6 million and $1.4 million during the same periods in 2024[121] - The provision for income taxes for the three months ended September 30, 2025, was 42.8%, compared to 41.2% for the same period in 2024, while for the nine months, it was 34.5% in 2025 versus 49.2% in 2024[122] - The effective tax rate difference for the nine months ended September 30, 2025, was primarily due to a decrease in foreign losses year over year and favorable adjustments to valuation allowances[126] Cash Flow and Capital - Operating activities provided cash of $25.4 million for the nine months ended September 30, 2025, compared to $13.1 million in the same period in 2024, primarily due to improved net income[137] - Investing activities used $4.1 million for the nine months ended September 30, 2025, compared to $8.8 million for the same period in 2024, related to capital expenditures[138] - Financing activities used $15.2 million for the nine months ended September 30, 2025, compared to $9.3 million for the same period in 2024[139] - As of September 30, 2025, working capital was $102.4 million, an increase from $94.9 million as of December 31, 2024[135] - The company had $95.6 million in cash as of September 30, 2025, with $89.8 million held in foreign markets[135] - The company maintains a revolving credit agreement with no outstanding balances as of September 30, 2025[141] Share Repurchase - The company repurchased 1,129,000 shares of common stock for $14.4 million during the nine months ended September 30, 2025, with a remaining balance of $19.3 million available for repurchases[140] Future Outlook - The company expects continued growth in international operations, significantly impacting total net sales[105]